Clinical Trial Update: A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors [Phase 1]

View source ↗

Summary

The document reports the completion of a first-in-human Phase 1 study evaluating multiple doses of BB-1701 in patients with locally advanced or metastatic HER2-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• BB-1701

Snippet

Sponsor: Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Conditions: Locally Advanced/Metastatic HER2 Positive Solid Tumors | Phase 1 | Status: COMPLETED